Phase II Study of TRC102 in Combination With Temozolomide for Recurrent Glioblastoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 14 Dec 2017
At a glance
- Drugs Temozolomide (Primary) ; TRC 102 (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- 13 Nov 2017 According to a TRACON Pharmaceuticals media release, data expepected in 2018.
- 17 Aug 2017 Planned primary completion date changed from 31 Aug 2017 to 31 Mar 2018.
- 10 Jun 2017 Biomarkers information updated